FDA
-
-
-
-
-
-
-
Relay Therapeutics (RLAY) and Elevar Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
-
-
-
-
-
-
-
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
-
-
-
-
-
-
-
Pre-Open Stock Movers: Bristol-Myers Jumps on FDA Approval, Carvana Gains on Upgrade
-
-
-
-
-
-
-
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

